Bone morphogenetic protein signalling activity distinguishes histological subsets of paediatric germ cell tumours

Authors

  • N. Fustino,

    1. Division of Hematology-Oncology, Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, Texas
    Search for more papers by this author
  • D. Rakheja,

    1. Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas
    Search for more papers by this author
  • C. S. Ateek,

    1. Division of Hematology-Oncology, Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, Texas
    2. Department of Molecular Biology, University of Texas Southwestern Medical Center, Dallas, Texas
    Search for more papers by this author
  • J. C. Neumann,

    1. Division of Hematology-Oncology, Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, Texas
    2. Department of Molecular Biology, University of Texas Southwestern Medical Center, Dallas, Texas
    Search for more papers by this author
  • J. F. Amatruda

    1. Division of Hematology-Oncology, Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, Texas
    2. Department of Molecular Biology, University of Texas Southwestern Medical Center, Dallas, Texas
    3. Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA
    Search for more papers by this author

James F. Amatruda, Departments of Pediatrics, Internal Medicine and Molecular Biology, UT Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX 75390-8534, USA. E-mail: james.amatruda@utsouthwestern.edu

Summary

Germ cell tumours (GCTs) are cancers of the testis, ovary or extragonadal sites that occur in infants, children and adults. Testicular GCT is the most common cancer in young men aged 15–40 years. Abnormalities in developmental signalling pathways such as wnt/β-catenin, TGF-β/BMP and Hedgehog have been described in many childhood tumours. To date, however, the status of BMP signalling in GCTs has not been described. Herein, we examine BMP-SMAD signalling in a set of clinically-annotated paediatric GCTs. We find that BMP signalling activity is absent in undifferentiated tumours such as seminomas and dysgerminomas, but robustly present in most yolk sac tumours, a differentiated tumour type. Gene expression profiling of TGF-β/BMP pathway genes in germinomas and yolk sac tumours reveals a set of genes that distinguish the two tumour types. There is significant intertumoural heterogeneity between tumours of the same histological subclass, implying that the BMP pathway can be differentially regulated in individual tumours. Finally, through miRNA expression profiling, we identify differential regulation of a set of miRNAs predicted to target the TGF-β/BMP pathway at multiple sites. Taken together, these results suggest that the BMP signalling pathway may represent a new therapeutical target for childhood GCTs.

Ancillary